Laboratory and Pathology Errors: When the Test Itself Causes the Harm

The Diagnosis Lives or Dies in the Lab

Biopsies, blood work, and cytology decide what gets treated, how aggressively, and how soon.

When the lab gets it wrong, the patient is treated for the wrong disease, or not treated at all.

Laboratory error takes forms most people never consider: a mislabeled tube, another patient's tissue on your slide, a misread biopsy, a critical result nobody called in.

Each one is measurable, and the medical literature has measured them.

Each one leaves a paper trail a malpractice case can follow.

Call (888) 713-6653 for a free case review if a lab or pathology result steered your care wrong.

Where Lab Errors Actually Happen: Before and After the Machine

The analyzer is the most reliable part of the process. Landmark quality research following tens of thousands of tests found confirmed errors in roughly 0.3 percent of analyses, distributed 62 percent before analysis, 15 percent during, and 23 percent after.^[1] The failure points are human ones.

Pre-Analytic: Collection and Labeling

The College of American Pathologists' multi-institution studies measured 0.92 labeling errors per 1,000 specimen labels.^[2] A mislabeled tube is not a paperwork problem; it is one patient's potassium or pathology assigned to another patient's chart, and every downstream decision inherits the swap.

Analytic: The Read Itself

Interpretation failures, a misread slide, a miscalled culture, dominate the pathology cases below. True instrument failure is rare and usually detectable from quality-control logs.

Post-Analytic: Reporting and the Critical Call

Laboratories maintain critical-value lists, results so dangerous they require immediate direct notification, and the benchmark studies show a median of five minutes from result to call. A dangerous potassium or a positive blood culture that never reached a clinician is a documented system failure, and the call logs show whether it happened.

The Wrong-Patient Biopsy: Mix-Ups, Floaters, and the DNA Answer

The error patients fear most is real and quantified. A prospective DNA study of roughly 13,000 prostate biopsies found occult specimen transposition between patients in 0.26 percent of cases and contamination with another patient's tissue in another 0.67 percent, just under 1 percent combined, across every practice setting studied.^[3] Pathologists also contend with floaters, stray tissue fragments carried between slides, found on 0.6 percent of slides in prospective review.

The remedy is as concrete as the error: DNA specimen provenance testing compares the biopsy tissue against the patient's own DNA and settles identity definitively. A patient treated for a cancer that a later test suggests was never theirs, or told they were clean while someone else's malignancy carried their name, has a case that modern genetics can prove.

Misread Pathology: What Second Opinions Reveal About First Reads

Pathology is interpretation, and interpretation varies more than patients are told. The Johns Hopkins mandatory second-review program found that re-examining outside cases changed the diagnosis seriously enough to alter treatment or prognosis in 1.4 percent of more than 6,000 cases.^[4] In a JAMA study of breast biopsy interpretation, pathologists agreed with the expert consensus 75 percent of the time overall, and only 48 percent of the time on atypia, the category that drives surveillance and preventive treatment decisions.^[5]

The harm runs in both directions. A missed malignancy grows untreated, the delayed-diagnosis pattern our cancer misdiagnosis page covers. A false positive sends a healthy patient into surgery, radiation, or chemotherapy they never needed, an injury the law treats every bit as seriously. In either direction, the slides still exist, and an independent expert re-read is how screening a case begins.

Screening-Test False Negatives: What the Pap Smear Evidence Shows

Federal evidence reviews found conventional Pap testing far less sensitive than the public assumed, with a best-estimate sensitivity around 51 percent in unbiased studies, and about two-thirds of false negatives caused by sampling rather than slide reading.^[6]

That matters legally in both directions. A single missed abnormal on a well-collected slide may be defensible science; a rescreening program that missed obvious abnormalities, or a lab whose workload and quality-control records show corners cut, is another matter. These cases are won and lost on the lab's own records: workload logs, rescreening rates, proficiency-test results, and the original slides.

Building the Case: CLIA Records, the Specimen Chain, and the Defendant List

Every clinical laboratory operates under federal CLIA regulation, which sets binding requirements for personnel, quality control, and proficiency testing. Inspection findings and statements of deficiency are discoverable, and a lab cited for the exact failure that injured the patient hands the case its strongest exhibit.

The defendants vary with the failure: the pathologist who misread, the laboratory company that mislabeled or understaffed, the hospital whose collection process swapped specimens, the practice that never transmitted the critical result. Hospital labs and outsourced reference labs raise the same employed-versus-contractor questions as every hospital case, mapped on our page about who answers for contractors inside a hospital. And because patients typically learn of a lab error only when a later test contradicts an earlier one, the discovery rule's timing machinery often decides whether the claim is alive; assume the clock is running from the day the contradiction surfaced.